Document is current

Article History

Accepted: 12 September 2021

First Online: 7 October 2021

Declarations

:

: This project was supported by The Ohio State University Comprehensive Cancer Center (P30CA016058); National Cancer Institute K12CA133250 (Coss) and R01CA201382 (Phelps); Eli Lilly Graduate Student Fellowship (Liva).

: CCC holds intellectual property concerning the use of REC-2282 (AR-42) and has received royalties associated with the licensing of this intellectual property to Recursion Pharmaceuticals. CCC has no direct financial relationship with Recursion Pharmaceuticals, and Recursion Pharmaceuticals did not contribute to this work in any way. CCH has received research grants from Oncolytics Biotech, research and personal grants from Janssen, BMS, Sanofi. Nektar, and Karyopharm, and personal grants from Imbrium and Oncopeptides over the last 24 months all outside the submitted work.

: All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments) and the details of the Ethics Committee or institutional review board which approved the studies.

: Not applicable.

: Not applicable.

: All data are included in the manuscript.

: Not applicable.

: AM, AW, KD, CH designed the clinical trials, accrued patients to the studies, and supported data acquisition, data analysis, and drafting of the manuscript; MP and CC directed the data analysis and supported drafting and editing of the manuscript; SL, MC and JW generated the PK data, performed the data analyses, drafted and edited the manuscript.